163 related articles for article (PubMed ID: 2819735)
1. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents.
Sullivan DM; Chow KC; Glisson BS; Ross WE
NCI Monogr; 1987; (4):73-8. PubMed ID: 2819735
[TBL] [Abstract][Full Text] [Related]
2. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
Sullivan DM; Latham MD; Ross WE
Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW
Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
6. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Barret JM; Calsou P; Larsen AK; Salles B
Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
[TBL] [Abstract][Full Text] [Related]
7. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
8. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
10. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
[TBL] [Abstract][Full Text] [Related]
11. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
12. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
13. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
Ross W; Rowe T; Glisson B; Yalowich J; Liu L
Cancer Res; 1984 Dec; 44(12 Pt 1):5857-60. PubMed ID: 6094001
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
15. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
16. Determination of DNA topoisomerase II activity from L1210 cells--a target for screening antitumor agents.
Wang LG; Liu XM; Ji XJ
Zhongguo Yao Li Xue Bao; 1991 Mar; 12(2):108-14. PubMed ID: 1663690
[TBL] [Abstract][Full Text] [Related]
17. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.
Hsiang YH; Wu HY; Liu LF
Cancer Res; 1988 Jun; 48(11):3230-5. PubMed ID: 2835157
[TBL] [Abstract][Full Text] [Related]
18. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts.
Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W
Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817
[TBL] [Abstract][Full Text] [Related]
19. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993
[TBL] [Abstract][Full Text] [Related]
20. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
Kerrigan D; Pommier Y; Kohn KW
NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
